Abstract (EN):
Dry eye syndrome or the keratoconjunctivitis sicca is a common disease of tear film and ocular surface developed in numerous aetiologies. Tear film instability and ocular surface disturbances that subsequently influence the tear film are among the primarily causes of this disease, but many other factors are involved in tear film disorders. Clinical manifestations commonly include eye discomfort, feeling of a foreign body in the eye, itching or even visual disturbance; inflammation and damage of ocular surface may follow. The therapeutic approaches are based on the dry eye symptoms relief, increasing the patient's comfort and preventing further damage to ocular surface. This can be achieved by renewing the normal function of tear film and ocular surfaces. Although eye surface is easily reached by classical ocular dosage forms, novel drug delivery systems for ocular administration offer advantages in terms of increased residence time on eye surface and/or controlled release of the drug, with enhanced therapeutic effectiveness. Patient's acceptance can also be improved by developing formulations that do not require frequent application, or cause blurred vision, and having a more pleasant appearance. Biodegradable, biocompatible, non-toxic, and mucoadhesive materials are being used for the design of colloidal carriers. Novel polymers for hydrogels suitable for ocular administration are reviewed in this chapter, giving overview on their potential benefits and limitations in dry eye syndrome management and reported successful formulations.
Language:
English
Type (Professor's evaluation):
Scientific